21 completed, 4 terminated, 4 unknown, 3 active not recruiting. 38 Phase 2, 4 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 38 | Completed 21, Terminated 4, Unknown 4, Active not recruiting 3, Recruiting 3, Withdrawn 3 |
| Phase 1 | 4 | Completed 2, Terminated 2 |
| Phase 3 | 1 | Recruiting 1 |
Follow Neoplasms, Unknown Primary: new trials by email Literature Review of Neoplasms, Unknown Primary trials Research Report on Neoplasms, Unknown Primary
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase II/III Study of F520 Combined With Paclitaxel Plus Carboplatin in the Treatment of Cancer of Unknown Primary (CUP) F520 combined with chemotherapy, placebo combined with chemotherapy - Cancer of Unknown Primary Site | Phase 2 / Phase 3 | Recruiting | Shandong New Time Pharmaceutical Co., LTD | 402 | 2026-07-08 | 2026-08-12 |
| A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer, in Patients With Unknown Primary Head and Neck Cancer (ILLUMINATE STUDY) Pegsitacianine - Head and Neck Cancer, Unknown Primary Cancer | Phase 2 | Recruiting | University of Texas Southwestern Medical Center | 120 | 2024-04-17 | 2026-04-14 |
| Sintilimab in Cancer of Unknown Primary Sintilimab - Cancer of Unknown Primary Site | Phase 2 | Completed | M.D. Anderson Cancer Center | 10 | 2021-08-26 | 2026-02-25 |
| Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors Spartalizumab, Tislelizumab - MSI-H Colorectal Cancer, Melanoma | Phase 2 | Active not recruiting | SOLTI Breast Cancer Research Group | 184 | 2021-04-12 | 2025-03-21 |
| Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity Atezolizumab - Breast Cancer, Lung Cancer | Phase 2 | Recruiting | British Columbia Cancer Agency | 50 | 2020-06-17 | 2026-09-16 |
| Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET. 177Lu-DOTATOC - Pulmonary Neuroendocrine Neoplasm, Pheochromocytoma | Phase 2 | Withdrawn | Excel Diagnostics and Nuclear Oncology Center | 2020-03-04 | 2023-03-10 | |
| Nivolumab/Ipilimumab in Second Line CUP-syndrome Nivolumab/Ipilimumab - Cancer of Unknown Primary Site | Phase 2 | Unknown | University Hospital Heidelberg | 194 | 2019-12-12 | 2020-04-15 |
| Trial of Pembrolizumab in Cancer of Unknown Primary Pembrolizumab - Cancer of Unknown Primary Site | Phase 2 | Completed | Imperial College London | 35 | 2019-02-22 | 2026-05-04 |
| Pembrolizumab in Patients With Poor-Prognosis Carcinoma of Unknown Primary Site (CUP) Pembrolizumab Injection - Carcinoma of Unknown Primary | Phase 2 | Completed | AHS Cancer Control Alberta | 33 | 2018-08-24 | 2026-07-02 |
| A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site Alectinib, Vismodegib, Ipatasertib - Cancer of Unknown Primary Site | Phase 2 | Completed | Hoffmann-La Roche | 529 | 2018-07-10 | 2025-11-19 |
| A Clinical Safety and Efficacy Study of Mebendazole on GI Cancer or Cancer of Unknown Origin. ReposMBZ - Cancer of the Gastrointestinal Tract, Cancer of Unknown Origin | Phase 1 / Phase 2 | Terminated | Repos Pharma | 11 | 2018-05-25 | 2020-01-22 |
| HARE-40: HPV Anti-CD40 RNA vaccinE BNT113 - Human Papilloma Virus Related Carcinoma, Head and Neck Neoplasm | Phase 1 / Phase 2 | Completed | University of Southampton | 30 | 2017-04-11 | 2026-10-07 |
| Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal Cord Computed Tomography, Quality-of-Life Assessment, Questionnaire Administration - Malignant Digestive System Neoplasm, Metastatic Head and Neck Carcinoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 60 | 2016-08-29 | 2026-10-07 |
| Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic Laboratory Biomarker Analysis, Pembrolizumab, Questionnaire Administration - Advanced Malignant Solid Neoplasm, Carcinoma of Unknown Primary | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 157 | 2016-08-15 | 2026-07-17 |
| Phase 2 Study of Gemcitabine and Docetaxel Combination Chemotherapy in Patients With Carcinoma of Unknown Primary gemcitabine/docetaxel combination - Carcinoma of Unknown Primary | Phase 2 | Unknown | Samsung Medical Center | 29 | 2015-10-01 | 2015-10-28 |
| A Study of Nab-paclitaxel-based Doublet as First Line Therapy in Patients With Cancer of Unknown Primary (CUP) nab-paclitaxel, Carboplatin, Gemcitabine - Unknown Primary Tumors | Phase 2 | Completed | Fondazione del Piemonte per l'Oncologia | 57 | 2015-03-01 | 2024-01-26 |
| Study to Compare Cardiovascular Side Effects of Teysuno Versus Capecitabine Teysuno, Capecitabine - Gastrointestinal Cancer, Cancer of Unknown Primary Site | Phase 2 | Completed | University of Edinburgh | 59 | 2014-02-05 | 2023-05-12 |
| Elective Mucosal Irradiation in Head-and-Neck Cancer of Unknown Primary Elective mucosal irradiaton - Head-and-neck Cancer, Carcinoma of Unknown Primary | Phase 2 | Unknown | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | 48 | 2010-01-01 | 2019-04-09 |
| Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary carboplatin, everolimus, paclitaxel - Carcinoma of Unknown Primary Origin | Phase 2 | Completed | Alliance for Clinical Trials in Oncology | 46 | 2009-09-01 | 2017-03-21 |
| Paclitaxel/Carboplatin With or Without Cetuximab in CUP paclitaxel/carboplatin, cetuximab - Neoplasms, Unknown Primary, Carcinoma | Phase 2 | Unknown | Heidelberg University | 150 | 2009-07-01 | 2009-05-14 |
Showing 20 of 38. Sign in to see all of them.
Head and Neck Neoplasms (7) · Squamous Cell Carcinoma of Head and Neck (5) · Gastrointestinal Neoplasms (4) · Sarcoma (4) · Carcinoma, Renal Cell (3) · Lung Neoplasms (3) · Carcinoma (2) · Carcinoma, Merkel Cell (2) · Carcinoma, Ovarian Epithelial (2) · Melanoma (2) · Neoplasms (2) · Paraganglioma (2) · Penile Neoplasms (2) · Pheochromocytoma (2)
Neoplastic Processes (38) · Pathologic Processes (38) · Pathological Conditions, Signs and Symptoms (38) · Neoplasm Metastasis (37) · Neoplasms (36) · Neoplasms by Site (14) · Neoplasms by Histologic Type (13) · Neoplasms, Glandular and Epithelial (12) · Carcinoma (10) · Digestive System Diseases (6) · Digestive System Neoplasms (6) · Female Urogenital Diseases (6) · Female Urogenital Diseases and Pregnancy Complications (6) · Gastrointestinal Diseases (6) · Male Urogenital Diseases (6)
Carboplatin (9) · Gemcitabine (9) · Paclitaxel (8) · Capecitabine (5) · Bevacizumab (4) · Cisplatin (3) · Erlotinib Hydrochloride (3) · Irinotecan (3) · pembrolizumab (3) · Amifostine (2) · CP protocol (2) · Filgrastim (2) · Fluorouracil (2) · Oxaliplatin (2) · Peripheral Blood Stem Cell Transplantation (2)
M.D. Anderson Cancer Center (4) · SCRI Development Innovations, LLC (3) · Alliance for Clinical Trials in Oncology (2) · Memorial Sloan Kettering Cancer Center (2) · AHS Cancer Control Alberta (1) · British Columbia Cancer Agency (1) · Burzynski Research Institute (1) · Copenhagen University Hospital, Rigshospitalet (1) · Dana-Farber Cancer Institute (1) · Eastern Cooperative Oncology Group (1) · Excel Diagnostics and Nuclear Oncology Center (1) · Fondazione del Piemonte per l'Oncologia (1) · Fox Chase Cancer Center (1) · Heidelberg University (1) · Hoffmann-La Roche (1)
United States (22) · Germany (4) · United Kingdom (4) · Denmark (3) · Canada (2) · China (2) · France (2) · Italy (2) · South Korea (2) · Spain (2) · Australia (1) · Austria (1) · Brazil (1) · Bulgaria (1) · Chile (1)
John D. Hainsworth, MD (3) · Matthew P. Goetz, MD (2) · Afshin Shafie, MD (1) · Alwin Kraemer, Prof. Dr. (1) · Andre A. Abitbol, MD (1) · Aung Naing (1) · Ayman Gaber, MD (1) · Christian Ottensmeier, Prof (1) · David G. Pfister, MD (1) · Ebrahim Delpassand, MD (1) · Elizabeth A. Poplin, MD (1) · Gauri R. Varadhachary, MD (1) · Gedske Daugaard, MD (1) · Harpreet Wasan, MBBS, FRCP (1)
PMID 17470864, PMID 19965914, PMID 20209610, PMID 22218909, PMID 22815703, PMID 26578722, PMID 31533818, PMID 31953927, PMID 32188704, PMID 32303619, PMID 32534809, PMID 33235314, PMID 33415580, PMID 33427689, PMID 33491277, PMID 33770291, PMID 34241781, PMID 34725215, PMID 35618285, PMID 35999229, PMID 36200668, PMID 37568622, PMID 37875494, PMID 39096924, PMID 40212844, PMID 41143139, PMID 41935492, PMID 42185570, PMID 42342409, PMID 42691436
2014 (1), 2017 (1), P30CA006516 (1), P30CA016672 (1), P30CA021765 (1), P30CA072720 (1), R01CA266146 (1)